newsfilter
← Latest News
Business Wire·

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

FDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach Enveric Biosciences (NASDAQ:ENVB) ("Enveric"